Table 2.
Multivariate Cox proportional hazards analyses of AST/ALT ratio on overall survival, cancer-specific survival, and recurrence-free survival.
| Variables | Overall survival | Cancer-specific survival | Recurrence-free survival | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | 1.03 (1.00-1.01) | 0.032 | 1.05 (1.01-1.09) | 0.022 | 1.01 (0.97-1.04) | 0.633 |
| BMI | 0.92 (0.84-1.01) | 0.099 | 0.92 (0.84-1.02) | 0.103 | 1.06 (1.00-1.13) | 0.043 |
| Tumor size | 1.16 (1.09-1.24) | <0.001 | 1.16 (1.09-1.24) | <0.001 | 1.13 (1.07-1.20) | <0.001 |
| High tumor grade | 1.58 (1.10-2.28) | 0.013 | 1.65 (1.09-2.49) | 0.017 | 1.30 (0.90-1.88) | 0.159 |
| ≥pT2 stage | 3.30 (1.18-9.21) | 0.022 | 5.78 (2.51-13.35) | <0.001 | 5.14 (2.05-12.90) | <0.001 |
| ≥N1 stage | 1.37 (1.06-1.77) | 0.014 | 1.35 (1.05-1.74) | 0.018 | 1.54 (1.20-1.97) | <0.001 |
| ≥M1 stage | 1.68 (0.23-11.99) | 0.605 | 3.89 (0.45-33.90) | 0.219 | 1.73 (0.22-13.58) | 0.604 |
| NACH | 1.21 (0.60-2.42) | 0.594 | 1.33 (0.63-2.78) | 0.191 | 1.86 (0.80-4.26) | 0.142 |
| AST/ALT ratio | ||||||
| AST/ALT ≤1.1 | Reference | Reference | Reference | |||
| AST/ALT >1.1 | 2.15 (1.23-3.73) | 0.007 | 2.05 (1.65-2.56) | <0.001 | 1.32 (0.69-2.56) | 0.087 |
BMI: body mass index; NACH: neoadjuvant chemotherapy; ALT: alanine aminotransferase; AST: aspartate aminotransferase.